In a paper published in Cell, UNC School of Medicine researchers led by Bryan Roth, MD, PhD, show how to activate only one kind of brain receptor vital for pain relief. This receptor is not involved in addiction or respiratory depression that leads to death – the most severe side effects of opioid use.
For the first time, scientists at the University of North Carolina School of Medicine and collaborators solved the crystal structure of the activated kappa opioid receptor bound to a morphine derivative. They then created a new drug-like compound that activates only that receptor, a key step in the development of better pain medications.
The research, published in the journal Cell, shows a route toward creating opioids that relieve pain without causing the severe side effects at the heart of the opioid epidemic.
Currently, most opioids bind to several opioid receptors on the surface of cells, and this is one of the main reasons why opioids relieve severe pain but also trigger a wide range of side effects from nausea, numbness, and constipation to anxiety, severe dependency, hallucinations, and even death caused by respiratory depression.
“To create better opioids, we need to know the structure of their receptors,” said senior author Bryan Roth, MD, PhD, the Michael Hooker Distinguished Professor of Protein Therapeutics and Translational Proteomics in the Department of Pharmacology at UNC-Chapel Hill. “Until recently, this was impossible. But now we know the structure of the activated kappa opioid receptor. And we showed we can actually use the structure to make a drug-like compound with better properties than current opioids.”
The work was done in cell cultures in Roth’s lab, and in the future researchers will test this and related compounds in animal models. Also, using the detailed structure of the kappa opioid receptor (KOR), Roth’s lab and other scientists could develop other drug-like compounds highly selective for specific opioid receptors now that the structure is available.
“Tens of thousands people who take opioids die every year, and so we need safer and more effective drugs for treating pain and related conditions,” Roth said. “One of the big ideas is to target KORs because the few drugs that bind to it don’t lead to addiction or cause death due to overdose. Those side effects are mainly related to actions at the mu opioid receptor.”
Drugs that do hit KORs can have other side effects, such as hallucinations and dysphoria – a general state of unease or dissatisfaction with life related to anxiety and depression. This is why scientists need to know how this receptor is activated – to figure out the best way to bind a compound to KORs to only relieve pain.
Two postdoctoral fellows in Roth’s lab led the work – first author Tao Che, PhD, and corresponding author Daniel Wacker, PhD, who collaborated with several other scientists at UNC and around the world.
Receptors are proteins on the surface of cells. About 40 percent of drugs currently on the market target G-protein coupled receptors, or GPCRs, such as KORs. Typically, scientists have solved the chemical structure of proteins using a technique called x-ray crystallography. They first figure out the best way to force the protein to condense into a tightly packed crystal lattice, then shoot x-rays at the crystal, and finally calculate the protein’s structure based on how the x-ray beams change direction. But it’s very difficult to do this with opioid receptors because they are so small and delicate, and they do not sit still when bound to a ligand, or drug-like compound. And the exact moment a scientist would want to see the structure of the activated receptor is when it is bound to a compound that will then cause a biological effect, like a key opening a door.
To overcome this difficulty, Wacker, Che, and colleagues used Lipidic Cubic Phase crystallization – suspending KOR molecules in specially designed water-lipid mixtures and then slowly removing the water. Then, in order to be sure the receptors were sitting perfectly still, the researchers employed a variety of experimental tricks, including the use of a tiny antibody to “prop up” the receptor in its active state bound to a ligand – a derivative of morphine created by Sush Majumder, PhD, at Memorial Sloan Kettering Cancer Center. Che figured out this derivative called MP1104 would work after he screened dozens of similar candidates from the same class of drugs.
Once they had the crystal structure in hand, Che, Wacker and colleagues could see which parts of the receptor were important for binding to drug-like compounds. Collaborators at the University of Southern California led by Vsevolod Katritch, PhD, used computer models of ligands to see which parts they could chemically modify to make the ligands more likely to bind tightly to KORs but not to other receptors. With those modifications made, they synthesized a new compound and showed in lab tests that it is extremely selective for KORs.
“Now we have a much better understanding of the direction we have to explore in order to create a selective drug to activate only kappa opioid receptors,” Wacker said.
Che added, “It’s now possible to design new drugs based on the findings on this active KOR structure and tweak them to only have the desired pain relief effects.”
The Latest on: Opioids
Massage Therapy As an Alternative to Opioids?
on June 13, 2018 at 8:06 am
When every muscle in the body hurts, it can be hard to relax. Even the smallest movements are excruciating, enough to make someone collapse into bed under the heaviness of their pain. Mental illness and addicition issues guide many people to opioids in an ... […]
Congress focus on opioids misses larger crisis
on June 12, 2018 at 8:03 pm
WASHINGTON — Congress faced a startling public health and political problem throughout 2016 as the number of people dying from opioid addiction climbed. The number of Americans succumbing to drug overdoses more than tripled between 1999 and 2015 ... […]
Cancer treatment: Will marijuana replace opioids?
on June 12, 2018 at 1:02 pm
Medical marijuana is still a controversial topic when it comes to doctors recommending it to their cancer patients. Some doctors like Dr. Nick Spirtos, an oncologist from Nevada is looking into whether medical marijuana could turn into an alternative for ... […]
Mass. Sues Purdue Pharma Over 670 Residents Who Fatally Overdosed On Opioids
on June 12, 2018 at 12:19 pm
State Attorney General Maura Healey announced Tuesday that Massachusetts is suing Purdue Pharma on behalf of 670 Massachusetts residents who were prescribed OxyContin, became addicted to opioids, overdosed and died. The 80-page complaint filed Tuesday in ... […]
Purdue Pharma 'created' the opioid epidemic: Read Mass. AG Maura Healey's lawsuit against maker of prescription opioids
on June 12, 2018 at 10:06 am
The prescription opioid manufacturer Purdue Pharma was hit with a lawsuit from Attorney General Maura Healey, who alleged that the company "created the [opioid] epidemic and profited from it through a web of illegal deceit." The lawsuit, which alleges ... […]
Will medical marijuana replace opioids in war on cancer?
on June 11, 2018 at 12:57 pm
President Trump recently told reporters he will likely support a congressional effort to end the federal ban on marijuana, which could finally help cut through the red tape blocking scientists from conducting large-scale trials on the benefits of medical ... […]
House panel questions FDA's track record combating illegal opioids
on June 11, 2018 at 8:38 am
WASHINGTON (Reuters) - U.S. lawmakers fear the Food and Drug Administration is not doing enough to stop the flow of illegal drugs into the United States as the country works to combat the opioid epidemic. Republican and Democratic members on the House ... […]
Q&A: Opioids crisis is backdrop to new play about Betty Ford
on June 11, 2018 at 3:48 am
BOSTON — It’s no exaggeration to say Betty Ford changed the national conversation about addiction. The former U.S. first lady, who died in 2011, established drug and alcohol treatment centers credited with helping generations of celebrities and ... […]
via Google News and Bing News